Viewing data from:

LEVOCARNITINE

ANDA

LEVOCARNITINE | A075567 | HIKMA PHARMACEUTICALS USA INC

1 strength0 unique patents0 unique exclusivities

Reference Listed Drug: CARNITOR(TE code: AP)

Medicare Part D Spending

CMS annual spending data for Levocarnitine (2023)

Total Spending

$3.6M

Total Claims

32,831

Beneficiaries

5,259

Avg Cost/Unit

$0.84

Spending Trend

$4.2M(2019)→$1.5M(2019)→$4.1M(2020)→$1.6M(2020)→$4.2M(2021)→$1.7M(2021)→$2.0M(2022)→$3.7M(2022)→$3.6M(2023)→$2.0M(2023)

YoY Change:-2.7%

5yr CAGR:+0.2%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain9 active DMFs2 inactive

9 active API suppliers hold Drug Master Files for this ingredient.

ACETO CORPLEVOCARNITINE USP

DMF 161502002

CHENGDA PHARMACEUTICALS CO LTDLEVOCARNITINE USP

DMF 191422006

PHARMARESOURCES (KAIYUAN) CO LTDLEVOCARNITINE

DMF 367462022

SS PHARMA LLCLEVOCARNITINE USP

DMF 370332022

API PHARMA TECH LLCLEVOCARNITINE USP

DMF 371662022

METROCHEM API PRIVATE LTDLEVOCARNITINE USP

DMF 389932023

GLAND PHARMA LTDLEVOCARNITINE

DMF 391682023

ZHEJIANG BAMBOO PHARMACEUTICALS CO LTDLEVOCARNITINE

DMF 393752024

SHIJIAZHUANG CANSAV PHARMACEUTICAL TECHNOLOGY CO LTDLEVOCARNITINE

DMF 408032024

LONZA BIOTEC SROInactiveLEVOCARNITINE TARTATE

DMF 140891999

NORTHEAST GENERAL PHARMACEUTICAL FACTORYInactiveLEVOCARNITINE

DMF 201022006

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
Mar 29, 2001	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — 200MG/ML

0 patents0 exclusivities▴

INJECTABLE;INJECTION | Approved: Mar 29, 2001

No patent or exclusivity listings for this strength.